FRM
NRIX icon

Fox Run Management’s Nurix Therapeutics NRIX Stock Holding History

Fox Run Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
+14,489
New +$240K 0.04% 748
2025
Q3 		– Sell
-18,902
Closed -$215K – 1137
2025
Q2 		$215K Buy
+18,902
New +$204K 0.04% 736

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Fox Run Management's NRIX Position: Q1 2026 in Review

Fox Run Management opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 14,489 shares worth $213K. The stake represents 0.04% of the portfolio and ranks #748 among its holdings. This is a return to the name: Fox Run Management previously reported a position in NRIX as recently as Q2 2025.

Fox Run Management first reported a position in NRIX in Q2 2025 and has held it in 2 quarters since. The position peaked at $215K in Q2 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Fox Run Management held 14,489 shares of Nurix Therapeutics worth $213K as of Q1 2026.
  • Nurix Therapeutics was a new Fox Run Management position in Q1 2026.
  • Nurix Therapeutics made up 0.04% of Fox Run Management's portfolio in Q1 2026, its #748 holding.
  • Fox Run Management first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Fox Run Management's Nurix Therapeutics position peaked at $215K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.